NEW YORK (GenomeWeb News) – Saladax Biomedical today announced Ilex Medical will exclusively distribute three of its tests in Israel.

Under the agreement, Ilex will distribute My5-FU, MyPaclitaxel, and MyDocetaxel diagnostic reagent kits, which are designed to measure the level of the chemotherapy drugs in blood "to overcome the limitations associated with dosing based on body surface area," or BSA, Saladax said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.